Constructs for enhancing immune responses

Patent metadata

Field	Value
Publication number	US-9724406-B2
Application number	US-201514628784-A
Country	US
Kind code	B2
Filing date	Feb 23, 2015
Priority date	Aug 28, 2006
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.

First claim

The invention claimed is:

1. A fusion protein, wherein the fusion protein comprises:
a first polypeptide segment comprising at least amino acids 1-240 of a mature Herpes simplex virus (HSV) glycoprotein D, wherein the first polypeptide segment does not comprise a full length glycoprotein D;
a second polypeptide segment comprising at least one antigen, wherein the at least one antigen is not an HSV glycoprotein D antigen, wherein the N terminus of the second polypeptide segment is linked to the C terminus of the first polypeptide segment; and
a third polypeptide segment comprising a C terminal portion of the HSV glycoprotein D, wherein the N terminus of the third polypeptide segment is linked to the C terminus of the second polypeptide segment.

2. The fusion protein of claim 1 , wherein the HSV is HSV-1.

3. The fusion protein of claim 2 , wherein the first polypeptide segment comprises amino acids 26-265 of SEQ ID NO:27.

4. The fusion protein of claim 1 , which comprises the amino acid sequence SEQ ID NO:24.

5. The fusion protein of claim 1 , wherein the second polypeptide segment comprises an E5 protein, an E6 protein and an E7 protein from HPV.

6. The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence SEQ ID NO:23.

7. The fusion protein of claim 1 , wherein the fusion protein comprises the amino acid sequence SEQ ID NO:22.

8. The fusion protein of claim 1 , wherein the fusion protein is encoded by the nucleic acid sequence SEQ ID NO:32.

9. The fusion protein of claim 1 wherein the fusion protein comprises the amino acid sequence SEQ ID NO:33.

10. The fusion protein of claim 1 , wherein third polypeptide segment comprises the transmembrane domain of the HSV glycoprotein D.

11. A method of inducing an immune response, comprising providing to a subject in need thereof a fusion protein of claim 1 .

12. The method of claim 11 , wherein the fusion protein is provided by administering to the subject a nucleic acid molecule which encodes the fusion protein.

13. The method of claim 11 , wherein the fusion protein comprises the amino acid sequence SEQ ID NO:24.

Assignees

• Wistar Inst

Inventors

• Ertl Hildegund C J
• Lasaro Marcio O
• Ferreira Luis C S

Classifications

• A61P31/22

  for herpes viruses · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C12N2710/16634

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K14/005

  from viruses · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title